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ABSTRACT
Objective: This study was undertaken to estimate the annual direct costs ofcomplications associated
with bacterial vaginosis (BV) in pregnant women in the United States.
Methods: An economic model was developed from evidence in the published literature linking
perinatal complications to BV. The estimates of attributable risks were applied to the estimated
population of pregnant women in the United States in 1993. The charge data from a database of
hospital utilization information were then used to estimate the direct costs of each pregnancy
complication and the total direct costs associated with BV.
Results: Under the assumptions ofour model, the direct costs ofpreterm labor, preterm delivery,
the attendant low birth weight (LBW), and other perinatal complications associated with BV were
estimated at nearly $1.0 billion in 1993. Over 40% of the total cost was associated with preterm
delivery and intensive care ofLBW infants, while another 24.5% of the cost was related to preterm
labor.
Conclusions: If the current frequency of BV among pregnant women persists and BV is not
detected and treated during pregnancy, the projected annual costs will reach $1.4 billion by the year
2000. Reducing the heavy economic burden associated with BV in pregnant women will require the
establishment of effective screening and treatment regimens. (C) 1995 Wiley-Liss, Inc.
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ver the past decade, a growing body of evi-
dence has suggested that bacterial vaginosis
(BV) increases the risk of preterm birth and other
perinatal complications. To date, 6 published stud-
ies have reported an increased risk of preterm birth
among women with this common vaginal syn-
drome. The link between preterm birth and BV
reported in these case-control’ or cohort
-6 stud-
ies supports a strong epidemiologic consistency.
These studies were conducted in populations of
pregnant women in the United States, Scandinavia,
the United Kingdom, and Indonesia, representing
all ethnic groups and socioeconomic strata. While
the risks of preterm birth have ranged from 2.0 to
6.9 in these studies,
1-6 the link between preterm
birth and BV found in these studies cannot be ac-
counted for by other risk factors such as smoking,
history of pretevm birth, or access to prenatal care
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because a similar link between BV and prematurity
has been established in women without these risk
factors for preterm birth.
The mechanism by which BV causes preterm
delivery or low birth weight (LBW) is not known.
However, a substantial body of data demonstrates a
link between BV and upper-genital-tract infection
in pregnancy, including histologic chorioamnioni-
tis,
7 infection of the chorioamnion,
7 and amniotic-
fluid infection, s’8’9 These infections are common
complications of preterm delivery and predictors of
higher neonatal morbidity. BV has also been linked
with an increased risk of postcesarean endometri-
tis.
9
IfBV or other infectious morbidity represents a
preventable cause of preterm birth, the screening
and treatment of women with this syndrome would
prevent the health care costs associated with these
perinatal complications. The present study was un-
dertaken to estimate the costs associated with pre-
term birth and other infectious complications ofBV
in the absence of screening and treatment options.
In this report, we present an estimate of the
annual direct economic costs of BV in pregnant
women in the United States based on an analysis of
the published research and a database of hospital
discharge records jointly maintained by the Com-
mission on Professional and Hospital Activities
(CPHA) and Healthcare Knowledge Resources
(HCIA, Inc., Ann Arbor, MI). For this study, we
have assumed an etiologic role for BV in pregnancy
complications. The direct costs in our analysis refer
to health care costs for the goods and services used
to treat the putative effects of BV. The charges for
medical care are used to approximate these costs.
SUBJECTS AND METHODS
Frequency of BV in Pregnant Women
The population projections from the U.S. Bureau
of the Census provide an estimate of the number of
U.S. women of childbearing age ( 15-44 years old)
in 1993 of 58.8 million The U.S. fertility rate of
67 live births/I,000 women (15-44 years old) has
remained relatively stable in recent years. Assum-
ing that all live births are singletons, we can esti-
mate .that 3.9 million pregnant women had live
births in the United States in 1993. Eschenbach
estimates that 15-20% of pregnant women have
BV. Using the low end of this range, we can esti-
mate conservatively that there were 585,000 cases
ofBV in the pregnant population in 1993.
Frequency of Specific Perinatal Complications
and Risk Attributable to BV
The costs of BV-associated infections in pregnant
women can be attributed to episodes of preterm
labor and delivery with or without premature rup-
ture of the membranes (PROM) and the associated
delivery ofLBW infants. The link between BV and
LBW was assumed to be due to preterm LBW
since BV was not linked to intrauterine growth
retardation in a cohort ofover 13,000 women.
12 In
addition, BV in pregnant women is associated with
amniotic-fluid infection and postpartum endome-
tritis and their attendant costs. Table summarizes
the results of our literature search for the strength
of association between BV and each of these peri-
natal complications. -6’8’9’3’4 The annual fre-
quency of the diagnosis of these perinatal compli-
cations in the U.S. pregnant population and the
proportion of each complication that might be attri-
buted to BV are presented in Table 2. 1-6’8’9’14’15
The risk of a complication attributable to BV was
not consistently available in the literature we in-
cluded in our investigation. Using the available
data on the incidence of a complication in the study
population and in those without BV, we calculated
an attributable risk. If more than one attributable
risk was available for a complication, a U.S. popu-
lation attributable risk specific to BV was given the
highest priority. If several attributable risks could
be calculated for a complication from individual
studies, a weighted average was used.
Direct Costs
The cost estimates for the complications of preg-
nancy related to BV were supplied by HCIA, Inc.,
which provides database services utilizing the clin-
ical database of CPHA. CPHA’s clinical database
is nationally recognized as a major source for com-
prehensive diagnosis and procedure data and clini-
cal utilization norms and standards. Approximately
1,000 short-term, nonfederal, general hospitals in
the United States submit data on a regular basis to
CPHA.
All hospitals submitting information with valid
charge data during the calendar year 1991 were
eligible for this study. The actual occurrences of
specific labor, delivery, and newborn diagnostic
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TABLE I. Evidence linking perinatal complications to BV
Reference No. Year OR or RR (95% CI) P value
Preterm labor
Gravett et al. 534 1986
McGregor et al.
14 202 1990
Kurki et al.4 790 1992
Preterm delivery
Gravett et al.
3 88 1986
Martius et al. 212 1988
Kurki et al.
4 790 1992
Riduan et al. 490 1993
Hay et al. 467 1994
Hoist et al. 87 1994
Preterm PROM
Gravett et al. 534 1986
Kurki et al.
4 790 1992
Amniotic-fluid infection
Gravett et al. 534 1986
Silver et al.
8 125 1989
Watts et al.
9 462 1990
Postpartum endometritis
Watts et al. 462 1990
OR 2.0 (I. I-3.5) <0.05
RR 2.6 (I.I-6.5) 0.03
OR 2.6 (.3-4.9) <0.0
OR 3.8 (.2- .6) <0.05
oR 2.3 (. -s.o) 0.03
OR 6.9 (2.5-18.8) <0.001
OR 2.0 (I.0-3.9) <0.05
OR 5.5 (2.3-13.3) <0.01
OR 2. (I.2-3.7) <0.05
OR 2.0 (I. I-3.7) <0.05
OR 7.3 (I.8-29.4) <0.001
OR 2.1 (I.2-3.9) <0.05
OR 2.6 (I.I-4.1) 0.05
OR 7.7 (3.4-16.9) <0.001
OR 5.8 (3.0-10.9) <0.01
aOR odds ratio; RR relative risk; CI confidence interval.
TABLE 2. Complications associated with BV in pregnancy
Complications Rate of complication (%)
Population attributable
risk percent for BY
Preterm laborz’4’4 10.0 23.0
Preterm delivery ’z’4-6’ 14 8.0 30.0
Preterm PROMz’ls 2.0 19.0
Amniotic-fluid infectionZ’8’9 6.0 15.0
Endometritis 5.0 33.0
codes were tallied, along with the mean and stan-
dard deviation for the aggregated length of stay and
total charges for each principal code. The costs
were based on the hospital charges for an admission
with each principal diagnostic code, including de-
livery inpatient charges and pediatric inpatient
charges. Contributing data to the report were 407
hospitals representing all sections of the United
States.
Based on the 1991 data from HCIA, Inc., the
mean estimated charge for threatened premature
labor without delivery (ICD-9-CM Code 644.0)
was $2,517. These premature labor cases were seri-
ous enough to require at least full day of hospital-
ization, and the mean length of stay was 2.7 days.
The mean charge for a normal delivery (ICD-
9-CM Code 650) was $2,298, with a mean length
of stay of 1.8 days.
The data for complicated deliveries were parti-
tioned into those delivered by cesarean and those
delivered vaginally. Within each delivery category,
the occurrence of a complication, length of stay,
and charge data were presented by the ICD-9-CM
code for each complication (preterm delivery, am-
niotic infection, and major puerperal infection).
Since the charges for complications associated with
deliveries were incorporated with the delivery charges,
we subtracted the mean 1991 charge for a normal
delivery from the charges for complicated vaginal
deliveries and the mean charge for an uncomplicated
cesarean delivery from charges for complicated cesar-
ean deliveries. In order to reflect the proportion of
complicated deliveries requiring cesarean (20%)com-
pared with vaginal, we used a weighted average ofthe
charges for vaginal deliveries (80%) and cesarean
deliveries (20%) for each complication.
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For example, the mean charge for an early onset
vaginal delivery (ICD-9-CM Code 644.2), de-
fined as a birth before the completion of 37 weeks
gestation, was $3,515, while the mean charge for
an early onset cesarean delivery was $8,127. Sub-
tracting the mean charges for uncomplicated deliv-
eries, the mean excess charge for early onset vaginal
delivery was $1,217 and the mean excess charge for
early onset cesarean delivery was $3,761. The
weighted average charge for a preterm delivery,
regardless of delivery method, was then estimated
to be $1,726 in 1991. A similar method was used
to calculate the weighted average charges for early
onset of delivery with PROM (ICD-9-CM Code
644.2 + 658.1 or 658.2) which was $2,210 and
amniotic-fluid infection (ICD-9-CM Code 658.4)
which was $1,888.
Major puerperal infections (ICD-9-CM Code
670.0) include postpartum endometritis which oc-
curs much more frequently in patients undergoing
cesarean delivery than in patients who deliver vagi-
nally. As a result, we used a weighted average of
charges that was partitioned at 55% for vaginal deliv-
eries and 45% for cesarean deliveries. The estimated
charge for postpartum endometritis, regardless of de-
livery method, was calculated to be $3,081 for 1991.
Since we assumed that BV is associated with the
delivery of preterm LBW infants, we incorporated
the charge for ICD-9-CM Code 765.1 (other pre-
term infants) of $19,757 into our cost accounting
which represented a mean length of stay for the
preterm infant of 18 days. This ICD-9-CM code
for preterm LBW represented 95% of the occur-
rences ofLBW in this sample of the database. To
estimate the cost of the complication of preterm
LBW among these infants, we subtracted the
charges for normal and healthy infants. In 1982,
Fuchs and Perreault16 estimated the direct money
costs of normal infant medical care as $64 for pedi-
atric care and an average hospital charge of $100
per day or $340 total. Adjusting these costs for medi-
cal care inflation over the 10 years and the reduction
in length of stay from a mean of 3.4 days to 1.8 days,
the direct medical costs for normal infants in 1991
was estimated at $479; this amount was subtracted
from the mean charges for preterm infants to arrive at
the estimate of the preterm LBW infants.
All 1991 charge data have been adjusted for
1992 using the overall medical care inflation rate of
6.6%.
17
Sensitivity Testing
To evaluate the limitations of these data, we ana-
lyzed the sensitivity of the results to the assump-
tions. First, the assumption of independence among
the pregnancy complications was varied to look at
the effect of double counting the cost of events
occurring in individual patients. Second, the cost
input data were varied 50% on either side of the
1991 mean charges for the various labor, delivery,
and newborn complications included in the model
in order to account for cost outliers that shift the
means significantly one direction or another. In
addition, the effect of discounting the hospital
charges to align them with the payments for the
complications was explored.
RESULTS
The excess risk of pregnancy complications in
women with BV was estimated from the published
studies summarized in Table 1. The increased risk
of preterm labor among women with BV in pub-
lished studies has ranged from 2.0 to 2.6, while the
risk for preterm delivery has ranged from 2.0 to
6.9 (Table 1). Other complications including pre-
term PROM, amniotic-fluid infection, and post-
partum endometritis occurred 2-7 times more fre-
quently among women with BV compared with
women without this syndrome (Table 1).
The population attributable risks, which were esti-
mated from the studies using the decision rules noted
in Subjects and Methods, are summarized in Table 2.
Based on the U.S. population projections sug-
gesting that 3.9 million pregnant women would
have live births in 1993, we estimated the number
of patients with pregnancy complications related to
BV and the costs of those complications (Table 3).
For these estimates, the assumption was made that
the excess risks ofpregnancy complications reported
for women with BV are attributable to BY.
We also assumed in this base-case analysis that
each of the perinatal complications occurs indepen-
dently, resulting in an estimate of slightly fewer
than 300,000 pregnancy complications attributable
to BV; the costs of these complications are estimated
to be $982 million for 1993. If, in fact, each
pregnancy complication occurs independently, we
can conclude that about 50% of the 585,000 preg-
nant women with BY have been affected by these
perinatal complications. This assumption may re-
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TABLE 3. Economic model for BV in pregnant women
Complication
No. of patients Cost per Total costs
with BV-associated complication (in millions)
complications case per complication
Preterm labor 89,700 $ 2,683 $240.7
Preterm delivery 93,600 $ 1,840 $172.2
LBW infants 12,255 $20,581 $252.2
Preterm PROM 14,820 $ 2,356 $ 34.9
Amniotic-fluid infection 35,100 $ 2,013 $ 70.7
Endometritis 64,350 $ 3,284 $211.3
Total costs $982.0
a1991 charges adjusted for the rate of medical care inflation in 1992.
sult in some excess patient counts and costs being
attributed to complications ofBV since some patients
will have more than one complication, costing collec-
tively less than the sum of the excess cost for each
complication. For example, a delivery after PROM
may also involve an amniotic-fluid infection. We have
chosen to deal with the effects of the independence
assumption through sensitivity analysis.
Over 40% of the total direct costs estimated to be
associated with BV in pregnant women involved the
costs of preterm delivery and the attendant costs of
intensive care for preterm LBW infants. Nearly a
quarter of the costs were related to preterm labor
(24.5%), while the remaining third of the costs
were associated with preterm PROM, amniotic-
fluid infection, and postpartum endometritis.
Projections Through 2000
Assuming a constant rate of overall medical care
inflation equal to the low level in 1993 (5.4%) and
a constant BV incidence rate of 15% and retaining
all other assumptions from the original model, we
project that the direct costs of BV in pregnant
women will reach $1.4 billion by the year 2000, as
shown in Figure 1. If the incidence rate of BV-
associated complications in pregnant women de-
creases 1% per year over the 8-year period as a
result of changes in the population or effective
screening and treatment, direct costs of about $1.3
billion are projected. If a more substantial decrease
(! 0%) occurs in the rate of BV-associated complica-
tions in pregnant women each year, the direct costs
could drop to approximately $679 million.
Sensitivity Testing
Table 4 presents the results of the sensitivity analy-
sis. In the column "1991 Cost Inputs," we have
presented the base-case analysis. The next 2 col-
umns present the alternative analyses, looking at
extreme estimates. A key source of uncertainty in
the assessment of the cost ofBV in pregnant women
is the extent to which the perinatal complications
presented in Table 4 occur concomitantly within
the same patient. For example, the epidemiology of
these complications suggests that preterm LBWs
are accompanied by preterm labor or preterm
PROM. 18,19 There is further evidence that two-
thirds of preterm deliveries are caused by preterm
labor or preterm PROM.2’2 We have used these
probabilities for the likelihood of double counting
in this model and assigned the lowest possible costs
to each combination of perinatal complications to
produce the outer range (minus 50%) for the anal-
ysis. The cost input data were also varied 50% on
either side of the 1991 mean charges, adjusted for
1992 medical care inflation, to account for cost
outliers that may have shifted the means for each
pregnancy complication significantly one direction
or another. That analysis suggests that the direct
costs of BV-associated complications of pregnancy
varied between $491 million and $1.5 billion in
1992 inflation-adjusted dollars.
In order to evaluate the limitations of using
charge data rather than payment data for direct
costs, we assumed that the difference between hos-
pital charges and payments ranges from 5 to 10%.
We reduced the 1992 inflation-adjusted charge data
for each complication by 5% and 10% to reflect the
direct costs of BV-associated complications if actual
payment data had been used instead of charges;
these cost figures are presented in the last 2 columns
ofTable 4. With all incidence and attributable risk
estimates held constant, the estimated direct costs
based on payment data ranged from $884 to $933
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Fig. I. Projected annual direct costs of BV-associated pregnancy complications based on predic-
tions of the inflation rate and incidence changes. Squares no change in incidence and constant low
rate of inflation (5.4%); circles 1% decrease in incidence per year and constant low rate of inflation;
triangles 10% decrease in incidence per year and constant low rate of inflation.
TABLE 4. Sensitivity analysis: Projected costs of BV-associated pregnancy complications assuming different
cost inputs
Complication 1991 cost inputs Cost 50% Cost + 50% Cost 5% Cost 10%
Preterm labor $ 2,683 $ 1,342 $ 4,025 $ 2,549 $ 2,415
Preterm delivery $ 1,840 $ 920 $ 2,760 $ 1,748 $ 1,656
LBW infants $20,581 $10,291 $30,872 $19,552 $18,523
Preterm PROM $ 2,356 $ 1,178 $ 3,534 $ 2,238 $ 2,120
Amniotic-fluid infection $ 2,013 $ 1,007 $ 3,020 $ 1,912 $ 1,812
Epdometritis $ 3,284 $ 1,642 $ 4,926 $ 3,120 $ 2,956
Total costs $982 million $491 million $1,473 million $933 million $884 million
a1991 charges adjusted for the rate of medical care inflation in 1992.
bUses the most conservative assumptions from the analysis.
million for the BV-associated complications of preg-
nancy. Thus, the use of charge data may inflate the
total cost estimate by $50 million to $100 million
due to costs unrelated to actual patient care.
DISCUSSION
Our analysis indicates that the direct economic cost
ofBV infections in pregnant women in the United
States is nearly $1.0 billion annually. Although no
studies are available for comparisons, the estimate
we have computed is conservative for several rea-
sons. First, we used the figures representing the
lower range of incidence for BV detected at various
stages of gestation in the pregnant population. Sec-
ond, we have considered numerous confounding
variables, i.e., socioeconomic factors, black race,
young maternal age, other vaginal infections, and
previous pregnancy performance, present among
the cases of BV with complicated pregnancy out-
comes and have assigned a population attributable
risk to BV for the various pregnancy complications.
Third, the costs associated with postsurgical infec-
tion following pregnancy termination have not been
included since we have focused only on pregnancies
resulting in live births. Finally, no psychosocial
effects such as patient embarrassment, preoccupa-
tion with BV, or perceptions of the effect ofBV on
154 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYBACTERIAL VAGINOSIS IN PREGNANCY OLEEN-BURKEY AND HILLIER
sexual activity were included. Such costs are known
to exact a toll from patients and their families.
The reliability of the conclusions in this report
clearly depend on the accuracy of the estimates.
There are established epidemiologic criteria for de-
termining whether a risk (actor is causal for a given
outcome. One criterion is finding the association
consistently in different studies conducted in differ-
ent populations over time. Another is the magni-
tude of the relative risk showing that the exposure
occurs before the outcome. A further criterion is
biologic plausibility, showing a biologic gradient
in which increased exposure is associated with in-
creased risk.
The series of studies reviewed for the incidence
and attributable risks of pregnancy complications
related to BV included women from different eth-
nic and socioeconomic groups and consistently re-
ported an increased risk for preterm delivery or
LBW among women with BV. In several of the
cohort studies,
4-6 the assessment of BV was per-
formed in the first or second trimester of preg-
nancy, documenting that BV was diagnosed prior to
the onset of preterm labor. Likewise, the studies
consistently show the relationship between BV and
amniotic-fluid infection and postpartum endome-
tritis. The association between upper-genital-tract
infection and BV supports the biologic plausibility
of the association between the syndrome and pre-
term birth because one mechanism by which BV
causes preterm birth is thought to be by causing an
upper-genital-tract infection.
BV is a syndrome caused by replacement of the
vaginal lactobacilli by Gardnerella vaginalis, obli-
gately anaerobic bacteria including Prevotella
bivia, black-pigmented Prevotella and Porphyromo-
haS species, Bacteroides, and genital mycoplasmas.
The specific organisms associated with BV that are
responsible for preterm delivery are unclear, al-
though the anaerobic gram-negative rods are the
group of microorganisms most consistently linked
to preterm birth.
1,2 However, screening for vagi-
nal anaerobes by culture is technically difficult and
very expensive. Therefore, the use of the Gram-
stained vaginal smear as a surrogate for the culture
of anaerobic gram-negative rods is cost effective in
identifying most women with high concentrations
of vaginal anaerobes.
22
The impact of variation from the projected cost
data was investigated through the sensitivity analy-
ses. Varying the cost input data by as much as 50%
introduces substantial differences to our direct cost
estimates; however, even at the lower extreme of
minus 50%, the direct costs for BV-associated com-
plications of pregnancy are estimated at nearly $500
million. As has been common practice in the litera-
ture examining the costs of providing hospital ser-
vices, our study uses patient bills (charges) as a
proxy for cost instead of measuring the costs di-
rectly. The use of charges introduces bias to the
report, since hospital charge data include compen-
sation for debts, replacement of equipment and
facilities, free services, community programs, and
disallowed (for reimbursement) costs, which may
make the charges substantially more than the costs.
In addition, the charges are adjusted to get a desired
rate structure usually based on community norms.
The potential impact of the bias due to overstating
hospital costs on these results, which was also inves-
tigated with the sensitivity analyses, may represent
$50-$100 million of the direct-cost estimates.
With the known morbidity caused by BV infec-
tions, these economic cost results underscore the
need for effective BV treatment programs. The
costs of BV in pregnant women are due to the
consequences ofuntreated, uncomplicated infections
that could have possibly been prevented. Even with-
out increases in the incidence of BV, with no treat-
ment effort the cost of BV in pregnant women will
rise because of medical inflation. By 2000, the total
cost of BV in pregnant women will reach $1.4
billion if the annual medical care inflation rate
averages a low 5.4% from 1993 through 1999 and
the incidence of BV remains constant during this
period.
If the treatment ofBV in pregnant women can be
shown to reduce the incidence of these complica-
tions, then investments in treatment offer clear ben-
efits. Routine screening of the nearly 4 million
pregnant women in the United States each year
could be easily accomplished by the Gram-stained
vaginal smear.
23 At an estimated cost of $10 per
smear, the screening of all pregnant women would
cost $40 million annually. If 15% of the pregnant
women have BV, then 600,000 women would be
treated for this condition. With the costs of drug
treatment ranging from $8 to $28 per woman,
depending on the dosage and route of administra-
tion, the total drug treatment costs for all women
with BV in the United States would range from
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$4.8 to $16.8 million annually. Thus, screening
all pregnant women in the United States for BV and
subsequently treating those found to have the con-
dition could be accomplished for $45-$57 million
annually. The efficacy rate of oral metronidazole
and clindamycin for the treatment of BV in preg-
nancy is 76-92%.
24,25 If the effectiveness rate as-
sumption for these treatments is 65% and effective
treatment decreases the frequency of preterm deliv-
ery attributable to BV by 50%,
24 then a conserva-
tive estimate of potential cost savings, after ac-
counting for the costs of screening and treatment,
would be $150 million annually.
The mounting body of evidence linking BV to
pregnancy complications worldwide, combined
with the excess financial and emotional costs associ-
ated with prematurity, suggest several research ar-
eas that deserve attention. First, the optimal time
for screening and treatment has not been defined,
although at least 2 studies suggest that early screen-
ing in the first or second trimester may be more
predictive of preterm delivery than later screen-
ing. 4’5 This finding should be verified in a system-
atic way in other populations. Second, economic
parameters need to be applied to the results of re-
cently completed randomized treatment trials dem-
onstrating the effect of drug therapy for BV during
pregnancy in the prevention of pregnancy compli-
cations. 24’26 If these regimens are shown to de-
crease the incidence of pregnancy complications as-
sociated with BV, it will be possible to show the cost
savings accruing to the health care payers.
Physicians are urged to learn to recognize the
clinical signs of BV (milky vaginal discharge, a
vaginal pI-I >4.5, and the release of an amine odor
after the addition of 10% potassium hydroxide to
the vaginal fluid), to screen selected patients, and to
follow recommended treatment guidelines. Ulti-
mately, it is hoped that the appropriate treatment of
BV in pregnant women will be a cost-effective ap-
proach to reducing the incidence of preterm labor
and the delivery ofLBW infants.
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